GSK1070806 clinical trials
Also written GSK1070806.
How each study uses GSK1070806 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GSK1070806 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 2
GlaxoSmithKline (9) · University of Birmingham (1) · Cambridge University Hospitals NHS Foundation Trust (1)
Studies
Open first, then newest update. How each study uses GSK1070806 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative ColitisRecruitingPhase 1GlaxoSmithKlineNCT07747480Written as Aletekitug
- A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative ColitisRecruitingPhase 1GlaxoSmithKlineNCT07747467Written as Aletekitug (GSK1070806)
- Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.TerminatedPhase 2GlaxoSmithKlineNCT06447506Written as GSK1070806
- A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic DermatitisTerminatedPhase 2GlaxoSmithKlineNCT05999799Written as GSK1070806
- Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic DermatitisCompletedPhase 1GlaxoSmithKlineNCT04975438Written as GSK1070806
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age InclusiveCompletedPhase 1GlaxoSmithKlineNCT05590338Written as GSK1070806
- A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's DiseaseCompletedPhase 1/2University of BirminghamNCT03681067Written as GSK1070806
- Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal TransplantationTerminatedPhase 2GlaxoSmithKlineNCT02723786Written as GSK1070806
- Anti IL-18 (GSK1070806) in Behcet's DiseaseStatus unknownPhase 2Cambridge University Hospitals NHS Foundation TrustNCT03522662Written as GSK1070806
- First Time in Human Study of Intravenous Interleukin-18 AntibodyCompletedPhase 1GlaxoSmithKlineNCT01035645Written as GSK1070806
- Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DMCompletedPhase 2GlaxoSmithKlineNCT01648153Written as GSK1070806
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting2
- A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative ColitisNov 5, 2026NCT07747480
- A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative ColitisOct 28, 2026NCT07747467
Codes
What other systems call GSK1070806 · ClinicalTrials.gg INT000472
- MeSH (NLM) C000608195GSK1070806One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608195 | GSK1070806 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.